Company intelligence / Profile preview

Healthplus.ai

Amsterdam, North Holland, Netherlands

Ownership: Private
Development stage: Commercial

Overview

PERISCOPE, the company's main product, integrates with electronic health records to predict individual patient risk for post-surgical infections using AI. It has demonstrated high accuracy with an AUROC >0.85 and a negative predictive value above 97% for low-risk patients. The tool aims to reduce complications, readmissions, and costs by enabling early intervention.\n\nNo traditional clinical trial results as it’s a digital health/software platform.\n\nValidated and recalibrated per hospital population/protocols.

Therapeutic areas: Infectious Diseases
Modalities: Device (clinical decision support software)
Industry: Digital Health Medical Devices

Partnerships

Collaborations with top hospitals for validation/deployment of PERISCOPE (specific names not disclosed)

Beyond the preview

Go deeper on Healthplus.ai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Healthplus.ai.

Explore the full profile